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To the Editor:  59 
Approximately 10-15% of asthmatic adults belong to a group with severe refractory asthma and 60 
suffer from debilitating chronic symptoms, despite optimal standard asthma treatment.1  Unraveling 61 
the complex pathophysiology of severe asthma has proven to be a major research challenge.1 62 
There is growing interest in the role of airway epithelium and its interactions with inhaled 63 
aeroallergens and pathogens, in the pathogenesis of severe asthma.  64 
 65 
In a study of patients with severe asthma and healthy controls, we have recently shown that 66 
profound ciliary dysfunction and marked ultrastructural abnormalities of the airway epithelium are 67 
features of severe asthma.2 One potential consequence of these abnormalities is prolonged and 68 
more intense exposure of the airway epithelium to inhaled aeroallergens and pathogens. Moreover, 69 
given the marked epithelial disintegrity seen in patients with severe asthma and the ability of the 70 
proteolytically active substances such as the Dermatophagoides pteronyssinus allergens to cause 71 
disruption of the intercellular tight junctions, resulting in increased transepithelial permeability,3 the 72 
airway basal cells could also be exposed to inhaled allergens and pathogens. In this regard, we 73 
studied the effect (in terms of cytokine and chemokine release) of a common respiratory pathogen 74 
(Streptococcus pneumoniae) on primary airway basal cells of patients with atopic severe asthma 75 
and compared that to healthy controls. As a positive control, the cytokine and chemokine release in 76 
response to a common inhaled allergen (Dermatophagoides pteronyssinus allergen 1 [Der p 1]) by 77 
primary airway basal cells was also studied.   78 
 79 
Detailed methodology is given in this article’s Online Repository. Briefly, we studied 8 subjects with 80 
severe asthma and 6 healthy controls. Subjects with severe asthma met the American Thoracic 81 
Society criteria for refractory asthma,1 were current non smokers and had a smoking history of less 82 
than 10 pack years. Healthy controls were non smokers, had no history of respiratory disease and 83 
had normal lung function and PC20. Demographics and clinical detail were collected. All subjects 84 
underwent flexible bronchoscopy and using epithelial brushings taken from the bronchus 85 
intermedius, confluent monolayers of basal cell cultures were developed. The basal cells were 86 
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incubated with wild type Streptococcus pneumoniae (strain D39) at concentrations of 106 cfu/ml and 87 
107 cfu/ml for up to 4 hours at 37°C. For the control, basal cells were incubated with 400µl bronchial 88 
epithelial base medium (BEBM) (Clonetics, UK). The supernatants were harvested at one hour and 89 
four hours after incubation and stored at -70°C. Similarly, confluent monolayers of basal cells were 90 
incubated with LoToxTM Natural Der p 1 (Indoor Biotechnologies) at concentrations of 1 µg/ml and 5 91 
µg/ml for up to 24 hours. The supernatants were harvested at eight hours and 24 hours after 92 
incubation and stored at -70°C. Chemokines and cytokines in the supernatant were measured using 93 
a 96-well multispot assay (Meso Scale Discovery [MSD], Maryland, USA) using a high band 94 
MS6000 10 spot plate, using SECTOR Imager 6000 (MSD, Maryland, USA) according to the 95 
manufacturer’s instructions. The lower limit of detection was 1 pg/ml. 96 
 97 
The baseline characteristics of the subjects and the data on chemokine and cytokine release in 98 
response to Streptococcus pneumoniae and Der p 1, are given in the online repository tables E1 – 99 
E5. The release of cytokines and chemokines by airway basal cells of patients with severe asthma 100 
and healthy controls in response to Streptococcus pneumoniae and Der p 1 was time and dose 101 
dependent. The magnitude of release of chemokines CXCL8 (IL8), CCL11 (Eotaxin) and CCL26 102 
Eotaxin_3) in response to S pneumoniae by basal cells from healthy controls, was significantly 103 
higher (p<0.05), compared to that from severe asthma patients (see Figure 1). In contrast, the 104 
magnitude of release of chemokines CXCL8 (IL8), CCL11 (Eotaxin), CCL26 (Eotaxin_3) (see 105 
Figure 2); as well as CCL4 (MIP 1b), CCL5 (RANTES), CCL13 (MCP 4), CCL17 (TARC) and 106 
CCL22 (MDC) in response to Der p 1 by basal cells from patients with severe asthma, was 107 
significantly higher (p<0.05) compared to that from healthy controls. We observed a similar 108 
differential cytokine response (IL6 and IL1b) of basal cells from severe asthma patients and healthy 109 
controls, to Der p 1 and Streptococcus pneumoniae (Online repository table E4 & E5, Figure E3).  110 
 111 
In the context of profound ciliary dysfunction and epithelial disintegrity seen in patients with severe 112 
asthma,2 the differential chemokine response of severe asthma patients’ airway basal cells to Der p 113 
1 and Streptococcus pneumoniae that we observed in this study is of great interest due to two main 114 
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reasons.  Firstly, asthma has been shown to be an independent risk factor for invasive 115 
pneumococcal disease. 4, 5 It remains to be determined if the reduced CXCL8 release by asthmatic 116 
airway epithelium compared to that of healthy controls leads to a reduction in neutrophil influx and  117 
delayed bacterial clearance, thereby increasing the risk of invasive pneumococcal disease in 118 
patients with severe asthma. Secondly, it has been suggested that in individuals with atopic 119 
sensitization to aeroallergens, there may be an altered mucosal immune response to bacterial 120 
antigens. 6, 7 In recent studies, using a mouse model of allergic asthma, immunomodulatory therapy 121 
with Streptococcus pneumoniae vaccine has been shown to attenuate both Th1 and Th2 cytokine 122 
production. 8, 9  123 
  124 
In this study we did not attempt to elucidate the mechanisms underlying the basal cell response to 125 
Der p 1 or Streptococcus pneumoniae. It would be of interest to investigate the effect of aberrant 126 
chemokine mileu on epithelial injury-repair mechanisms and whether prior exposure of asthmatic 127 
airway epithelium to Streptococcus pneumoniae leads to an attenuated response to Der p 1. As we 128 
used different time points for assessing the epithelial response to Streptococcus pneumoniae and 129 
Der p 1, there remains the possibility that alterations in the epithelial response kinetics may be 130 
contributory to the differential response that we showed and this needs further investigation.  131 
 132 
In summary, our study shows that airway basal cells of patients with atopic severe asthma and 133 
healthy controls are capable of releasing chemokines and cytokines in response to Der p 1 and 134 
Streptococcus pneumoniae in a dose and time dependent manner. Though no major conclusions 135 
may be drawn from this small pilot study, the differential response of the asthmatic epithelium is of 136 
interest and may be further explored in the context of developing novel immunomodulatory 137 
therapeutic strategies for the treatment of allergic airway inflammation.   138 
 139 
 140 
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Figure legends 206 
 207 
Figure 1. Release of CXCL8 (Fig 1 A & B), CCL11 (Fig 1 C & D) and CCL26 (Fig 1 E & F) by 208 
primary respiratory basal cells of patients with severe asthma and healthy controls, in response to 209 
Streptococcus pneumoniae (D39) at 106 cfu/ml and 107 cfu/ml. A, C & E- CXCL8 response of basal 210 
cells at 1 hour post exposure; B, D & F- CXCL8 response of basal cells at 4 hours post exposure. 211 
Data expressed as median (IQR). 212 
† p<0.01 compared to corresponding values for severe asthma. 213 
 214 
 215 
Figure 2. Release of CXCL8 (Fig 1 A & B), CCL11 (Fig 1 C & D) and CCL26 (Fig 1 E & F) by 216 
primary respiratory basal cells of patients with severe asthma and healthy controls, in response to 217 
LoTox Der p 1, 1µg/ml and 5µg/ml. A, C & E- response of basal cells at 8 hours post exposure; B, D 218 
& F- response of basal cells at 24 hours post exposure. Data expressed as median (IQR). 219 
† p<0.01 compared to corresponding values for healthy controls. 220 
 221 
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